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Richard D Baird1* and Carlos Caldas1,2*Abstract
More women die from breast cancer across the world today than from any other type of malignancy. The clinical
course of breast cancer varies tremendously between patients. While some of this variability is explained by
traditional clinico-pathological factors (including patient age, tumor stage, histological grade and estrogen receptor
status), molecular profiling studies have defined breast cancer subtypes with distinct clinical outcomes. This mini-
review considers recent studies which have used genomics technologies in an attempt to identify new biomarkers
of prognosis and treatment response. These studies highlight the genetic heterogeneity that exists within breast
cancers in space and time.
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Personalized medicine, HeterogeneityThe genetic heterogeneity seen in breast cancer
has important clinical implications
In 2008 it was estimated that the annual number of new
breast cancer diagnoses globally was approximately 1.4
million, with just under half a million deaths. It has long
been recognized that the clinical course of breast cancer
varies tremendously between patients. Traditional clinico-
pathological variables, including tumor stage, grade and
estrogen receptor status, have been used for decades by
clinicians to help prognosticate and guide treatment of
their patients. In the last 30 years or so, a range of molecu-
lar biology technologies, including gene expression profil-
ing, have been used to define molecular subgroups of
breast cancer with distinct clinical outcomes [1-3]. These
studies have identified recurrent somatic abnormalities,
including gene mutations, copy number aberrations and
translocations, the most important of which has been the
ERBB2 amplification present in 15 to 20% of breast can-
cers [4]. This mini-review considers recent studies that
have used genomic technologies in an attempt to identify* Correspondence: richard.baird@medschl.cam.ac.uk;
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distribution, and reproduction in any mediumnew biomarkers of prognosis and treatment response for
patients with breast cancer.Recent next-generation sequencing studies
Whole-genome sequencing studies have reported tens of
thousands of somatic mutations in different cancers
[5-7]. The evidence suggests that only a small minority
of these are essential for cancer development (“driver
mutations”) with the majority having no significant bio-
logical impact (“passenger mutations”) [8]. In the clonal
evolution model of malignant progression first proposed
in 1976 by Nowell [9], different cancer clones within a
tumor are in constant competition, with the “fittest”
clones proliferating at the expense of “less fit” clones.
Key driver mutations are thought to provide a selective
advantage on a cell to facilitate its clonal expansion [9].
The degree of genetic heterogeneity within tumors
from individual patients in both space and over time is
increasingly well characterized [10]. In one early report
using whole-genome sequencing, Shah et al. examined
paired, metachronous tumors from a single patient with
advanced invasive lobular carcinoma of the breast, and
found 19 non-synonymous mutations present in meta-
static tumors that were not evident in the primary tumor
diagnosed nine years earlier [11].
Nik-Zainal et al. characterized the molecular profiles of
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quencing [12,13]. The authors used “most-recent common
ancestor” bioinformatics algorithms to infer changes in
mutation signatures over time. A key finding from these
studies was that each tumor contained a dominant clone
(>50% of cancer cells) which had a mutational profile very
different from those of other sub-clones [12].
Shah et al. examined genome aberrations in a series of
104 primary “triple-negative” breast cancers using
Affymetrix SNP6.0 arrays, RNA-seq and genome/exome
sequencing. These tumors are so called “triple-negative”
because they lack estrogen receptor, progesterone recep-
tor and ERBB2 amplification [14]. This study showed be-
yond doubt that this “catch-all” diagnosis of exclusion in
fact refers to a group of cancers that exhibit great gen-
etic heterogeneity. Interestingly, the abundance of som-
atic mutations in a given tumor did not correlate with
the proportion of the genome with copy number alter-
ations (CNAs).
Stephens et al. analyzed the genomes of 100 tumors for
copy number alterations and mutations in coding exons of
protein-coding genes [15]. The authors found correlations
among the number of somatic mutations, the age at which
cancer was diagnosed and tumor histological grade. New
driver mutations were found in nine cancer genes inc-
luding: AKT2, ARIDIB, CASP8, CDKN1B, MAP3K1,
MAP3K13, NCOR1, SMARCD1andTBX3 [15].
Banerji et al. focused on the use of whole exome se-
quencing to identify patterns of mutation and transloca-
tion from 103 breast cancers from a range of subtypes
[16]. The authors confirmed the presence of PIK3CA,
TP53, AKT1, GATA3 and MAP3K1 mutations, but also
identified a recurrent MAGI3-AKT3 fusion found most
commonly in ER/PR-negative, HER2-negative breast
cancers. Functional experiments showed that this fusion
gene caused constitutive activation of AKT kinase whichTable 1 Most frequently mutated breast cancer genes
Gene mutation Function
PIK3CA catalytic subunit of PI3 kinase; key signal transduction
enzyme involved in cellular growth, survival
and insulin signaling
TP53 tumor suppressor; key regulator of cell cycle,
DNA repair, apoptosis
GATA3 transcription factor which regulates luminal epithelial cell
differentiation in the mammary gland
MAP3K1 kinase that activates ERK and JNK kinase pathways
MLL3 histone-lysine N-methyltransferase involved in transcription
co activation
CDH1 cell-cell adhesion glycoprotein; loss-of-function mutations
in E-cadherin are a feature of lobular breast cancer
Summary of data from recent breast cancer sequencing studies cited in this mini-rewas amenable to therapy with a selective, small-molecular
AKT inhibitor [16].
In the largest breast cancer series reported to date, the
METABRIC study group performed an integrated analysis
of copy number and gene expression in discovery and val-
idation sets each containing approximately 1,000 primary
breast tumors, with long-term clinical follow-up [17].
Inherited genetic variants (single nucleotide polymor-
phisms (SNPs) and copy number variants (CNVs)), and
acquired somatic CNAs were associated with altered gene
expression in approximately 40% of genes. Importantly,
analysis of the combined DNA-RNA profiles revealed 10
different sub-groups with distinct clinical outcomes, which
reproduced in the validation cohort. These included sub-
groups not previously identified by first-generation gene
expression profiling studies, in particular with seven dis-
tinct subtypes of ER positive disease and a separation of
triple negative cancers into at least two subtypes [1]. In-
deed, there is increasing evidence that diagnosis of “triple
negative” breast cancer does not describe a single bio-
logical entity with distinct natural history. Rather, it refers
to a wide range of cancers with great genetic diversity,
which can be further classified into multiple subtypes [18].
In one study, the functional heterogeneity observed within
the stem-cell-like compartment of triple-negative breast
cancers revealed a 31-gene signature which was associated
with the development of metastatic disease [19].
In addition to studies using genomic techniques to
identify prognostic biomarkers, a number of studies are
emerging focused on the identification of biomarkers
that predict response to therapies. For example, Ellis et
al. performed whole exome and whole genome sequen-
cing on 31 and 46 samples collected in two neoadjuvant
aromatase inhibitor trials [20]. The most significant such
finding was that mutant GATA3 appeared to correlate
with treatment-induced anti-proliferative effect [20].Approximate mutation frequency (%)
Overall Luminal A Luminal B HER2-enriched Basal-like
25-36 40-45 29 39 9
27-37 12 29 72 80
4-11 14 15 2 2
3-8 13 5 4 0
al 7 8 6 7 5
7 9-10 5 5 0
view [14-17,20,21].
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be published is that of the Cancer Genome Atlas Network
[21]. The investigators analyzed tumor and germline DNA
samples from 825 primary breast cancers using orthogonal
techniques, with different subsets of patients assayed on
each of the following platforms: genomic DNA copy num-
ber arrays, DNA methylation, exome sequencing, mRNA
arrays, microRNA sequencing and reverse-phase protein
arrays. Analysis of the combined data from five platforms
suggested there were four main breast cancer classes, with
each of these subgroups characterized by significant mo-
lecular heterogeneity. Once again this study confirmed
that there were relatively few “high-frequency” somatic
mutations, with only three genes (TP53, PIK3CA and
GATA3) occurring at >10% incidence across all breast can-
cers. Table 1 summarizes the most common mutations
found in recent large sequencing studies of breast cancer.
Intriguingly, comparison of basal-like breast tumors with
high-grade serous ovarian cancers uncovered many mo-
lecular similarities. The authors concluded that “much of
the clinically observable plasticity and heterogeneity oc-
curs within, and not across, the major biological subtypes
of breast cancer”. However, when the cancers were classi-
fied into the 10 subtypes identified in METABRIC there
were clear patterns of cluster-specific mutational land-
scapes emerging, providing strong support for the new
molecular taxonomy of breast cancer.
It is important to note that high-quality next-generation
sequencing (NGS) studies are characterized by stringent
quality control measures, and study designs that include
enough patient samples for accurate assessment of low-
prevalence findings. NGS technologies continue to
evolve rapidly, driven by the requirement to reduce
assay times and cost, while providing sufficient depth
and coverage [22].
The need for repeat tumor biopsies
Clinical studies of tumor heterogeneity at the molecular
level, and clonal evolution over time, have been hampered
in the past by difficulties in accessing repeated tumor sam-
ples from different anatomical areas, and at different time-
points. Future studies may be facilitated by two recent de-
velopments. First, for patients with metastatic breast can-
cer, it is increasingly recognized that ER and HER2 status
can change over time, and that in selected cases, repeat
tumor biopsy is indicated on clinical grounds to determine
whether ER or HER2-targeted therapy should be consid-
ered [23]. Secondly, it may prove clinically useful to take
serial blood samples to sequence circulating tumor DNA
(ctDNA), as a less-invasive “liquid biopsy” [24]. New
ctDNA assays may have advantages over circulating tumor
cells, including greater sensitivity in monitoring tumor re-
sponse to therapy [25], and a strategy by which to eluci-
date mechanisms of drug resistance in the clinic [26].Conclusion: the best therapeutic strategy. All-out
war? Magic bullets? Or uneasy stalemate?
In contrast to metastatic breast cancer, Hodgkin’s lymph-
oma, testicular cancer and acute myeloid leukemia can be
cured using aggressive chemotherapy. However, this is not
true for the common metastatic solid tumors. Indeed,
high-dose chemotherapy strategies were pursued unsuc-
cessfully by many researchers in an attempt to completely
eradicate all cancer cells in a patient’s body [27]. These
strategies failed, some authors argue, because of the tre-
mendous genetic heterogeneity of cancers, their spatial
dispersion and adaptation to myriad local microenviron-
ments within the individual patient [28]. The suggestion is
that for oncologists to achieve the best possible outcomes
for their patients, there should be a fundamental change
to the canonical treatment approach. Eradication of a
dominant, chemosensitive clone may serve only to in-
crease the selective pressure within the tumor, leading to
expansion of chemoresistant clones. Rather than killing
the maximum number of cells possible, these authors sug-
gest we should be trying to kill the fewest necessary to
prevent tumor progression [28]. Others point to drug re-
sistance mechanisms which might be overcome through
identification of novel drug targets, the development of
new targeted therapies and the rational use of drug combi-
nations [29,30]. One thing, however, is clear; if we are to
achieve the promise of personalized medicine, clinical tri-
als will need to follow (with adequate patient numbers)
the genetic diversity within tumors which exists in space
and time, in relation to the outcomes achieved following
different systemic therapies.
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